Neuroendocrine Tumors

Combination Immune Blockade Promising in High-Grade Neuroendocrine Tumors: The DART “Basket” Clinical Trial

Phoebe Starr

August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO 2019 Highlights - Neuroendocrine Tumors

Atlanta, GA—In a phase 2 “basket” clinical trial, the combination of ipilimu­mab (Yervoy), a CTLA-4 inhibitor, and nivolumab (Opdivo), a PD-1 inhibitor, led to tumor shrinkage in 44% of patients with rare, aggressive, extrapancreatic high-grade neuroendocrine tumors (NETs), and the responses were durable. No responses were seen in low-grade tumors. These results come from the Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) study, which was presented at the 2019 American Association for Cancer Research annual meeting, by Sandip P. Patel, MD, DART Clinical Study Chair, and Deputy Director, San Diego Center for Precision Immunotherapy, Moores Cancer Center, UC San Diego Health, La Jolla, CA. [ Read More ]

Cabozantinib, a Multitargeted TKI, Active in Advanced Neuroendocrine Tumors

Charles Bankhead

April 2017, Vol 8, No 2 - Neuroendocrine Tumors

San Francisco, CA—The multitargeted tyrosine kinase inhibitor (TKI) cabozantinib (Cabometyx) demonstrated encouraging activity in patients with advanced neuroendocrine tumors (NETs), including patients who previously received sunitinib (Sutent) or everolimus (Afinitor), according to results from a phase 2 clinical trial, reported Jennifer A. Chan, MD, MPH, Clinical Director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute, Boston, MA, at the 2017 Gastrointestinal Cancers Symposium. [ Read More ]

Long-Term Data Support Safety of Lanreotide in Advanced Neuroendocrine Tumors

Charles Bankhead

April 2017, Vol 8, No 2 - Neuroendocrine Tumors

San Francisco, CA—Pooled data from 2 randomized clinical trials and several open-label extension studies confirmed the safety and quality-of-life effects of long-term (>12 months) use of the somatostatin analog lanreotide (Somatulin Depot) for advanced neuroendocrine tumors (NETs), including functioning and nonfunctioning NETs, reported Alexandria T. Phan, MD, Medical Oncologist, University of New Mexico Cancer Center, Albuquerque, and colleagues, at a poster session at the 2017 Gastrointestinal (GI) Cancers Symposium. [ Read More ]